Search Clinical Trials
By Condition
By Location (USA)
By Location (Other)
By Sponsor
Resources
Privacy Policy
About Us
Disclaimer
Trial of Micafungin (FK463) in Combination with Liposomal Amphotericin B (AmBisome) for Aspergillosis Clinical Trials References presented on Clinical Trials Search isn't meant to be a substitute for proven healthcare advice, trips or professional assistance using a genuine physician. We are not docs. Always confer with your physician about Trial of Micafungin (FK463) in Combination with Liposomal Amphotericin B (AmBisome) for Aspergillosis conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Trial of Micafungin (FK463) in Combination with Liposomal Amphotericin B (AmBisome) for Aspergillosis Clinical research trials and Trial of Micafungin (FK463) in Combination with Liposomal Amphotericin B (AmBisome) for Aspergillosis healthcare trials happen in hundreds of localities throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the potency of new drugs. The propose of the studies / projects is to answer particular human health questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to detect cures for all sorts of conditions, such as Trial of Micafungin (FK463) in Combination with Liposomal Amphotericin B (AmBisome) for Aspergillosis. Trial of Micafungin (FK463) in Combination with Liposomal Amphotericin B (AmBisome) for Aspergillosis Clinical Trials and other clinical trials allow volunteers to acquire healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Trial of Micafungin (FK463) in Combination with Liposomal Amphotericin B (AmBisome) for Aspergillosis clinical trial. Subjects frequently obtain the most expert healthcare possible for their Trial of Micafungin (FK463) in Combination with Liposomal Amphotericin B (AmBisome) for Aspergillosis condition. Risks are a reality, nevertheless, and can include more or frequent doctor trips, medical risks (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with stern guidelines to protect clinical trials patients.

Home > "T" Clinical Trials Conditions > Trial of Micafungin (FK463) in Combination with Liposomal Amphotericin B (AmBisome) for Aspergillosis

Trial of Micafungin (FK463) in Combination with Liposomal Amphotericin B (AmBisome) for Aspergillosis



Trial of Micafungin (FK463) in Combination with Liposomal Amphotericin B (AmBisome) for Aspergillosis

For Condition: Aspergillosis
Status: No longer recruiting
Sponsor(s): Fujisawa Healthcare, Inc. ,
Synopsis: The purpose of this study is to evaluate the safety and effectiveness of micafungin in combination with AmBisome as first-line therapy in the treatment of invasive aspergillosis.
Details: This will be an open-label, non-comparative study in at least 50 patients.
Eligibility:
Study Type:
  Interventional, Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: Inclusion Criteria - Have proven or probable systemic infection with Aspergillus species and have received no more than 96 hours of prior therapeutic doses of systemic antifungal therapy Exclusion Criteria - Has abnormal liver test parameters, e.g., AST or ALT > 10 times upper limit of normal - Has allergic bronchopulmonary aspergillosis, aspergillomas, or with sinus aspergillosis or external otitis who do not have evidence of tissue invasion - Has life expectancy of less than five days
Total Enrollment: 50

Location and Contact Information:


Additional Information:
Study ID Numbers:
  01-0-125; 
Study Start Date: October 2002
Record last reviewed: February 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00047827

Other Aspergillosis Studies:
1. Comparing the Effectiveness of Fluconazole and a New Medicine (FK463) in Preventing Fungal Infections in Bone Marrow Transplant Patients

2. Voriconazole to Prevent Systemic Fungal Infections in Children

3. Study of FK463 for the Treatment of Invasive Aspergillosis

4. Investigational Drug in Combination with Standard Antifungal Agent(s) for the Treatment of Salvage Invasive Aspergillosis

5. Trial of Micafungin (FK463) in Combination with Liposomal Amphotericin B (AmBisome) for Aspergillosis

Related Studies:

Other Aspergillosis Clinical Trials
Other Michigan Clinical Trials
Other Detroit Clinical Trials

Trial of Micafungin (FK463) in Combination with Liposomal Amphotericin B (AmBisome) for Aspergillosis

Modify your Search

  Other Aspergillosis Clinical Trials
  Other Michigan Clinical Trials
  Other Detroit Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103